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RNAi2011:  Gene  Regulation  by  Small  RNAs,  the  6
th 
international  Oxford  RNAi  conference,  was  held  at  St 
Hilda’s College, University of Oxford (UK), between 29 
and 31 March, 2011. Sessions covered a variety of topics 
and  provided  an  excellent  opportunity  to  discuss  and 
reflect upon recent developments in this fast-moving and 
promising field. A number of conference posters were also 
on  display  throughout  the  conference,  and  a  number  of 
trade stands gave conference participants the opportunity 
to learn about the latest product developments. 
 
DELIVERY AND TARGETING 
 
If the potential of small RNAs as therapeutic agents is to be 
realised,  the  development  of  powerful,  efficient  delivery 
methods are crucial. The conference opened with a series of 
talks describing novel techniques that show great promise as 
agents  to  deliver  small  interfering  RNAs  (siRNAs)  and 
microRNAs  (miRNAs)  to  target  cells.  Kostas  Kostarelos 
(University  of  London,  UK)  described  how  carbon 
nanotubes,  which  are  internalised  by  the  cell  without 
apparent damage to cellular structure, could be chemically 
functionalised  and  combined  with  siRNAs  to  form  gene-
silencing complexes that are effectively delivered to target 
cells. To illustrate this principle, he presented data showing 
effective in vivo delivery and knockdown in neurological 
conditions and xenografted cancer cells.  
 
Polyethylenimine (PEI) is a transfection reagent used to 
package siRNAs and plasmids. The potential for PEI in the 
delivery  of  miRNAs  was  discussed  by  Achim  Aigner 
(Philipps-University  Marburg,  Germany).  The  miRNAs 
can  be  effectively  packaged  and  delivered  in  vivo  to 
tumour  xenografts  in  mice.  The  effect  of  chemical 
modifications  on  the  efficiency  of  PEI  as  a  delivery 
vehicle is currently being investigated. 
Professor Andrew Miller (King's College, London, UK) 
gave an engaging overview of “what we think we know 
about RNAi delivery”. He described the use of synthetic 
ABCD nanoparticles in tumour imaging in vivo. The use 
of  siRNA-ABC  nanoparticles  for  in  vivo  delivery  of 
siRNAs to tumours, along with an associated phenotypic 
reduction  in  tumour  growth  rate,  was  also  presented. 
Roger  Adami  (Marina  Biotech  Inc,  USA)  presented  a 
dialkylated  amino  acid-based  (DiLA2)  delivery  system 
with  accompanying  data  demonstrating  efficient 
hepatocellular uptake and endosomal escape.   
 
Exosomes are small  vesicles secreted by cells that can 
transport  small  RNAs  and  proteins.  Samira  Lakhal-
Littleton  (University  of  Oxford,  UK)  described  how 
exosomes  can  be  harnessed  for  delivery  of  siRNA 
molecules to the mouse brain with the aim of knocking 
down  expression  of  BACE1,  a  therapeutic  target  in 
Alzheimer's  disease.  Exosomes  were  obtained  from 
dendritic  cells  engineered  to  produce  the  exosomal 
membrane  protein  Lamp2b  fused  to  RVG,  a  neuron-
specific peptide. After introduction of BACE1 siRNA to 
the exosome by electroporation and intravenous transfer 
of  exosomes  to  wild-type  mice,  gene-specific  knock-
down was observed in target brain cells (Alvarez-Erviti 
et al, 2011).  
 
RNAi MODULATION FOLLOWING DELIVERY 
 
Georg  Sczakiel  (University  of  Lübeck,  Germany) 
reminded us that efficient delivery of siRNAs to a cell is 
not the only hurdle to an efficient therapeutic application 
of RNAi. Once inside a cell only a minority of the siRNAs 
are actually free in cytosol and available for silencing of 
target  RNAs.  He  described  methods  that  affect  the 
proportion  of  siRNAs  released  within  cells.  He  also 432 
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described  recent  results  showing  the  influence  of  cell 
stress on Ago2 localisation and RNAi efficiency (Detzer et 
al, 2011).  
  
Mirko  Ludwig  (Friedrich-Schiller-University  of  Jena, 
Germany)  described  the  development  of  ‘intelligent’ 
siRNAs  and  the  formation  of  the  spinoff  company 
BianoScience.  By  coupling  siRNAs  to  short  peptides 
containing the target site of a cell type-specific peptidase, 
it  is  possible  to  prevent  the  RNA-induced  silencing 
complex (RISC) from forming and thus prevent siRNAs 
from exerting their silencing effect. When these siRNA-
peptide complexes are introduced to cells, cleavage of the 
peptide, RISC formation and siRNA-mediated silencing is 
observed  only  in  cells  containing  the  peptidase 
corresponding  to  the  specific  peptidase  recognition 
sequence. This principle was demonstrated by binding a 
peptide  containing  the  target  sequence  for  caspase-4, 
which is expressed in Jeg-3 choriocarcinoma and MCF-7 
mammary  cancer  cells  but  not  HEK  (human  embryonic 
kidney)  cells.  Knockdown  of  Signal  Transducer  of 
Activation (STAT3) was only achieved in cells expressing 
the caspase-4 peptidase (Koehn et al, 2010).   
 
CHARACTERISATION OF miRNAs: 
ANNOTATION, FUNCTION AND TARGET 
IDENTIFICATION 
 
miRNAs  regulate  gene  expression  by  binding  to  target 
regions  within  messenger  RNA (mRNA)  molecules. This 
can  lead  to  degradation  of  the  mRNA  target  or  to 
translational repression via  mechanisms that have  not  yet 
been fully elucidated (Huntzinger et al, 2011). Although it is 
predicted that up to 45,000 conserved miRNA target sites 
exist in the 3'UTR of genes across the human genome, the 
overwhelming majority of these target genes have not been 
validated. Caspar Robinson (Sigma-Aldrich Life Sciences, 
USA) described how MISSION® 3'UTR Lenti GoClones 
and human miRNA mimics can be used for this purpose and 
illustrated  his  talk  with  data  demonstrating  validation  of 
known and conserved miRNA targets.   
 
One common method of investigating the role played by 
miRNAs is to block their action and examine the resulting 
effects on gene expression. Anti-miRNA Oligonucleotides 
(AMOs) can achieve this via a steric blocking mechanism. 
Mark  Behlke  (Integrated  DNA  Technologies  Inc,  USA) 
described a novel chemical modifying group that has been 
shown to improve potency and nuclease resistance whilst 
maintaining  a  high  level  of  specificity  in  an  in  vitro 
environment,  with  in  vivo  action  currently  under 
investigation.   
 
Sam  Griffiths-Jones  (University  of  Manchester,  UK), 
creator and curator of miRBase, described recent changes 
to  the  miRNA  database,  including  the  incorporation  of 
publicly available sequencing data. Users will now also be 
able to search for miRNA species expressed in a tissue or 
at a developmental stage of interest. Intriguing data from 
deep sequencing concerning arm-switching mechanisms in 
miRNA were also presented, with the predominant mature 
miRNA  product  formed  by  miR-10  hairpin  precursors 
shown to vary dramatically between species. The preferred 
product was shown to be dictated by sequences within the 
pri-miRNA  sequence but not  within the  mature  miRNA 
molecule (Griffiths-Jones et al, 2011).   
 
SMALL RNAs AND BIOLOGY 
 
In  the  first  of  the  conference's  two  keynote  speeches, 
Professor Sir David Baulcombe (University of Cambridge, 
UK)  presented  work  carried  out  in  Arabidopsis  that 
demonstrates the remarkable mobility of siRNAs and the 
role this might play in virus resistance.  
 
Until  recently,  it  was  believed  that  as  well  as  lacking 
nuclei and ribosomes, erythrocytes completely lacked all 
species  of  RNA.  Andrew  Hamilton  (University  of 
Glasgow, UK) presented his recent data showing that red 
blood cells in fact contain a considerable quantity of small 
RNA  that  is  stable  upon  cell  lysis,  and  most  of  which 
represent  known  miRNAs.  He  is  currently  investigating 
this  intriguing  phenomenon  and  the  biological  function 
that erythrocyte miRNAs may play.   
 
Johannes  Grillari  (University  of  Natural  Resources  and 
Applied Life Sciences, Vienna, Austria) presented data on 
the  miRNAs  released  when  cells  become  senescent. 
Interestingly,  the  primary  miRNA  identified  is  found  in 
elevated  levels  in  the  serum  of  elderly  volunteers 
compared  to  younger  ones.  He  also  described  potential 
downstream  consequences  in  cells  that  take  up  these 
circulating miRNAs.  
 
Natalia  Botchkareva  (University  of  Bradford,  UK) 
described  work  exploring  the  role  of  miRNAs  in  hair 
follicle development. She presented evidence that miR-31 
is required for correct hair follicle formation and that it 
regulates bone morphogenic protein (BMP) signalling.  
 
RNAi AS A HIGH-THROUGHPUT TOOL 
 
Steve Brown (University of Sheffield, UK) discussed the 
facilities  and  services  available  at  the  University  of 
Sheffield RNAi Screening Facility (SRSF) and how these 
can benefit researchers seeking to carry out genome-wide 
screens  in  Drosophila  cells.  He  also  described  the 
application  of  high  content  microscopy  to  genome-wide 
RNAi screens in Drosophila, with the aim of uncovering 
the functions of genes.   
 
David  Horn  (London  School  of  Hygiene  and  Tropical 
Medicine, UK) presented RNAi target sequencing (RIT-
seq),  a  high-throughput  phenotyping  technique  that  uses 
Illumina  sequencing  to  examine  changes  in  expression 
levels associated with >90,000 targets within the African 
trypanosome  genome  after  RNAi  induction.  As  well  as 
determining functions for a large number of previously-
uncharacterised genes, these data also provided a number 
of new drug  targets and  suggested putative  mechanisms 
for drug resistance (Alsford et al, 2011).   
 
SMALL RNAs, CANCER AND CELLULAR STRESS 
 
The importance of miRNAs in cancer is well documented, 
and several presentations focused on advancements in our 433 
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understanding  of  miRNA  deregulation  during  tumour 
progression.  Cervical  cancer  can  be  triggered  by  the 
human papillomavirus (HPV). John O’Leary (University 
of Dublin, Ireland) presented an intriguing account of how 
knocking down a specific HPV gene leads to an altered 
transcriptional profile in cervical cells, findings which may 
have therapeutic implications. In the second part of his talk 
he  described  the  role  of  miR-21  in  mediating 
chemoresistance  in  ovarian  cancer.  This  microRNA 
appears  to  regulate  the  innate  immune  TLR4/MyD88 
pathway (Sheedy et al, 2010).   
 
In  the  second  keynote  presentation,  Adrian  Harris 
(University of Oxford, UK) discussed new data relating to 
a  mechanistic  role  for  mirR-210  in  tumour  growth  and 
survival in vitro and in the adaptive response to hypoxic 
conditions. miR-210 has previously been associated both 
with  hypoxia  and,  independently,  with  an  aggressive 
phenotype  and  lower  chances  of  survival  in  breast  and 
head and neck cancers.  Recent work has suggested several 
targets for miR-210; these include crucial genes required 
for  mitochondrial  chaperone  function,  for  example  iron 
sulphur  complexes  necessary  for  enzymes,  such  as 
aconitase and members of the electron transport chain, and 
DNA repair pathways (Favaro et al, 2010).  Data relating 
to  miRNAs  that  are  down-regulated  under  hypoxic 
conditions were also presented. 
 
In  addition  to  their  function  as  regulators  of  gene 
expression,  there  exists  the  possibility  that  circulating 
miRNAs  may  act  as  biomarkers  for  specific  conditions.  
Yaping  Tian  (Chinese  PLA  General  Hospital,  China) 
presented  details  of  how  specific  serum  miRNAs  were 
investigated as potential biomarkers for liver pathologies.  
miR-885-5p was found to be significantly elevated in the 
sera  of  patients  with  hepatocellular  carcinoma  (HCC), 
liver  cirrhosis  (LC)  and  chronic  hepatitis  B  (CHB)  as 
compared  to  healthy  controls  and  therefore  has  the 
potential  to  act  as  a  biomarker  for  detection  of  liver 
pathologies (Gui et al, 2011).   
 
THERAPEUTIC APPLICATIONS OF SMALL RNAs 
 
Short  activating  RNAs  (saRNAs)  are  designed  to  up-
regulate  expression  of  their  target  genes.  Nagy  Habib 
(Imperial College, UK) described the potential of saRNAs 
in manipulating the transcriptional identity of stem cells. 
This could have therapeutic potential to treat a range of 
diseases.  Patrick  Lu  (Siranomics,  USA)  presented 
remarkable  data  on  the  use  of  siRNAs  to  inhibit  scar 
formation  following  mechanical  wounds  or  burns.  The 
approach  involves  knocking  down  genes  involved  in 
inflammation  by  topical  application  of  siRNA 
nanoparticles. This demonstrates the potential of RNAi as 
a therapeutic tool in the near future.  
 
TECHNOLOGY FOCUS 
 
Two  afternoon  workshops  provided  the  opportunity  for 
delegates to learn about the latest developments in image 
analysis from Molecular Devices and in RNAi and gene 
knock-out  techniques  from  Sigma-Aldrich.    MetaXpress 
application  modules  and  PowerCore  distributed  image 
analysis  software  were  demonstrated  by  Christian  Holz 
(Molecular  Devices,  USA)  using  the  results  of  a 
micronuclei  assay.  Caspar  Robinson  (Sigma-Aldrich, 
USA)  and  colleagues  described  a  number  of  recently-
developed technologies that provide new opportunities for 
gene  silencing.  These  included  the  generation  of  SAGE 
animals  and  CompoZr  cell  lines,  the  latter  of  which 
involves custom zinc-finger nucleases (ZFNs) that are pre-
designed and pre-validated.   
 
CONCLUDING REMARKS 
 
The conference's attendees bore  witness  to a number of 
exciting breakthroughs, particularly in the areas of RNAi 
delivery.  Andrew  Miller  (King's  College,  London,  UK), 
who presented lifetime achievement awards to Professor 
Sir David Baulcombe (University of Cambridge, UK) and 
Professor  John  O’Leary  (University  of  Dublin,  Ireland), 
accurately  summed  up  the  challenges  and  opportunities 
faced by all who wish to use RNAi as a therapeutic tool. 
Progress is slow but steady, but we must continue to invest 
in the potential of RNAi and have faith that our efforts will 
bear fruit in the years to come. We will return in 2012 to 
review our progress. 
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